Inolitazone (RS5444; CS-7017) is a novel high-affinity PPARγ agonist with potential antiproliferative and antitumor activities; it inhibits tumor growth in xenograft models of anaplastic thyroid carcinoma (ATC) in a dose-dependent manner; it demonstrates additive antiproliferative effects when combined with paclitaxel in vitro; it upregulates the cell cycle kinase inhibitor p21WAF1/CIP1 in a PPARγ-dependent manner; it suppresses DRO and ARO tumor growth in vivo when administered orally in diet after tumor establishment.